Introduction {#section5-1753466619840256}
============

Postoperative acute lung injury (ALI), characterized by the acute onset of hypoxemia with radiographic pulmonary infiltrates without a clearly identifiable cause, is a major cause of morbidity and mortality after lung resection surgery.^[@bibr1-1753466619840256],[@bibr2-1753466619840256]^ Many studies have reported that approximately 2--8% of patients develop ALI after lung resection surgery for lung cancer.^[@bibr2-1753466619840256][@bibr3-1753466619840256][@bibr4-1753466619840256][@bibr5-1753466619840256]--[@bibr6-1753466619840256]^ Despite its relatively low incidence, the mortality from ALI following lung resection remains high.^[@bibr1-1753466619840256],[@bibr2-1753466619840256]^

The clinical and radiologic characteristics of postoperative ALI are identical to those of acute respiratory distress syndrome (ARDS).^[@bibr7-1753466619840256][@bibr8-1753466619840256]--[@bibr9-1753466619840256]^ Therefore, treatment of postoperative ALI is based on the management strategies of ARDS, which include general supportive care with lung protective ventilation and restrictive fluid management.^[@bibr1-1753466619840256],[@bibr10-1753466619840256]^ Unfortunately, no pharmacologic therapy for ARDS has been shown to reduce either short-term or long-term mortality;^[@bibr10-1753466619840256]^ however, corticosteroids may improve gas exchange and hasten radiographic improvement in patients with ARDS.^[@bibr11-1753466619840256][@bibr12-1753466619840256][@bibr13-1753466619840256][@bibr14-1753466619840256]--[@bibr15-1753466619840256]^ Although a high-dose short course of corticosteroids for early-phase ARDS failed to show improvements in survival,^[@bibr16-1753466619840256],[@bibr17-1753466619840256]^ a recent trial using a low-dose prolonged course of corticosteroids in early ARDS demonstrated improvement in organ dysfunction and a reduction in duration of mechanical ventilation (MV) and length of stay in the intensive care unit (ICU).^[@bibr14-1753466619840256]^ The beneficial effects of early low-dose corticosteroids have been reported in patients with postoperative ALI after lung resection surgery;^[@bibr18-1753466619840256]^ however, there are limited data on the benefit of early administration of corticosteroid in patients with ALI after lung resection surgery.

The objective of this study was to investigate the beneficial effects of early (within 72 h) treatment with corticosteroids in patients with postoperative ALI compared with late treatment. Our hypothesis was that fibroproliferation, which is an early response to lung injury, would be inhibited by early corticosteroid treatment without serious adverse events.

Patients and methods {#section6-1753466619840256}
====================

Study population {#section7-1753466619840256}
----------------

Data were collected from all consecutive patients diagnosed with postoperative ALI after lung resection surgery for lung cancer at Samsung Medical Center (a 1989-bed referral hospital in Seoul, South Korea) from January 2009 through December 2016 and retrospectively analyzed. The institutional review board of the Samsung Medical Center approved the review and publication of information obtained from the patients' records (approval no: 2017-01-018). Informed consent was waived because of the retrospective observational nature of the study. All patient data were anonymized and de-identified by the data coordinator prior to analysis.

Diagnosis of postoperative ALI {#section8-1753466619840256}
------------------------------

During the study period, postoperative ALI was diagnosed by (1) sudden onset of respiratory distress within 7 days after surgery; (2) diffuse pulmonary infiltrates on chest computed tomography (CT); (3) impaired oxygenation with partial pressure of arterial oxygen (PaO~2~)/fraction of inspired oxygen (FiO~2~) ratio (PF ratio) \<300 mmHg; (4) symptoms not fully explained by cardiac failure or fluid overload.^[@bibr5-1753466619840256]^ Serum brain-type natriuretic peptide and transthoracic echocardiography were performed to exclude pulmonary edema of cardiac origin. Other causes of respiratory distress such as respiratory/systemic infection were excluded. Severity of ALI was classified by the Berlin definition in patients receiving MV.^[@bibr19-1753466619840256]^

Data collection {#section9-1753466619840256}
---------------

The medical records of the patients were reviewed and clinical data were extracted, including demographic characteristics, body mass index, smoking history, American Society of Anesthesiologists physical status, comorbidities (chronic obstructive pulmonary disease, interstitial lung disease, hypertension, diabetes mellitus, and other malignancies), predicted postoperative pulmonary function tests, clinical stage, and the presence of neoadjuvant treatment (radiotherapy or chemotherapy). The following perioperative data were also extracted: side of resection, approach type, type of operation, total operation time, one lung ventilation (OLV) time, peak airway pressure during OLV, tidal volume during OLV, intraoperative volume, transfusion, and bleeding volume. The following variables were measured at the initiation of corticosteroid therapy (day 0): Sequential Organ Failure Assessment (SOFA) score,^[@bibr20-1753466619840256]^ PF ratio, lung injury score (LIS), oxygenation index, MV settings (FiO~2~, positive end-expiratory pressure, support pressure), monitored tidal volume, serum C-reactive protein (CRP), and arterial blood gas analysis. At day 2 and 7 from the initiation of corticosteroid therapy, the SOFA score, PF ratio, LIS, and oxygenation index were measured. We also extracted data on complications such as newly diagnosed delirium assessed by the Confusion Assessment Method for the ICU (CAM-ICU),^[@bibr21-1753466619840256]^ superimposed infection, and surgical site complications during corticosteroid treatment, and treatment modalities during ICU stays including antibiotics, vasopressor, tracheostomy, continuous renal replacement therapy, and extracorporeal membrane oxygenation.

Corticosteroid treatment and treatment outcomes {#section10-1753466619840256}
-----------------------------------------------

During the study period, postoperative ALI was managed by a multidisciplinary team composed of thoracic surgeons, pulmonologists, and intensivists. The team decided the administration of corticosteroid when the diagnosis of postoperative ALI was confirmed, and patients suffered from hypoxemia demonstrating PF ratio of \<300 mmHg. We classified patients into two groups according to the time of initiation of corticosteroid treatment: the early treatment group received corticosteroid within 72 h, and the late group received corticosteroid more than 72 h after ALI occurred. A loading dose of methylprednisolone 1--2 mg/kg was followed by infusion of 1 mg/kg/day from day 1 to day 14, 0.5 mg/kg/day from day 15 to day 21, 0.25 mg/kg/day from day 22 to day 25, and 0.125 mg/kg/day from day 26 to day 28.^[@bibr14-1753466619840256]^ Before the protocol of corticosteroid treatment was implemented at our institution, the loading dose was decided at the discretion of the attending physicians. Regarding loading dose, methylprednisolone doses of ⩽2 mg/kg and \>2 mg/kg were defined as low-dose and high-dose corticosteroid treatment, respectively.

Response to corticosteroid treatment was defined as weaning from MV within 7 days or improvement in LIS of more than 1 point by day 7. For patients remaining intubated on day 7, improvement in lung function was defined as follows: a reduction in LIS by 1 or more point and a day 7 LIS ⩽2.0 (for study entry LIS ⩽2.9) or ⩽2.5 (for study entry LIS ⩾3.0) as previously described.^[@bibr14-1753466619840256]^ For patients not receiving MV, LIS was calculated using two components: chest X-ray score and hypoxemia score. In addition, we documented outcomes of patients with ALI including length of stay at the ICU and hospital, and 28-day, ICU, and hospital mortality.

Statistical analysis {#section11-1753466619840256}
--------------------

Data are presented as the median and interquartile range (IQR) for continuous variables and as frequency (percentage) for categorical variables. Data were compared by the Mann--Whitney *U* test for continuous variables and by the Pearson's Chi-square test or Fisher's exact test for categorical variables.^[@bibr22-1753466619840256]^ All tests were two-sided and a *p* value \<0.05 was considered significant. Duration of MV curves for each treatment group were estimated by the Kaplan--Meier method and compared by the log-rank test. Data were analyzed using IBM SPSS Statistics for Windows, version 23.0 (Armonk, NY, USA).

Results {#section12-1753466619840256}
=======

During the study period, a total of 7593 patients underwent lung resection surgery for lung cancer and 58 (0.8%) patients developed ALI. Preoperative and perioperative characteristics are summarized in [Table 1](#table1-1753466619840256){ref-type="table"}. Among the 58 patients, 53 (91%) were male and the median age of all patients was 70 years (IQR, 62--72 years). A total of 11 (19%) patients received neoadjuvant treatment before operation. Overall, 36 (62%) patients received a right-side operation. Regarding the type of operation, 7 (12%) patients underwent pneumonectomy, 4 (7%) underwent bilobectomy, 43 (74%) underwent lobectomy, and 4 (7%) underwent wedge resection. The early treatment group contained 42 (72%) patients and the late treatment group contained 16 (28%). There were no significant differences in preoperative and perioperative characteristics between the two groups.

###### 

Preoperative and perioperative data for patients with acute lung injury after pulmonary resection.

![](10.1177_1753466619840256-table1)

  ------------------------------------------------------------------------------------------------------------
                                       Total\              Early treatment\    Late treatment\     *p* value
                                       (*n* = 58)          (*n* = 42)          (*n* = 16)          
  ------------------------------------ ------------------- ------------------- ------------------- -----------
  Age, years                           70 (62--72)         70 (61--72)         71 (63--74)         0.508

  Male                                 53 (91)             38 (91)             15 (94)             1.0

  BMI, kg/m^2^                         22.3 (20.2--24.5)   23.1 (20.2--25.3)   22.0 (19.3--23.3)   0.175

  Smoking history                                                                                  0.905

   Ex-smoker                           32 (55)             22 (52)             10 (63)             

   Current smoker                      21 (36)             16 (38)             5 (31)              

  ASA physical status                                                                              0.120

   1                                   5 (9)               4 (10)              1 (6)               

   2                                   41 (71)             32 (76)             9 (56)              

   ⩾3                                  12 (21)             6 (14)              6 (38)              

  Comorbidities                                                                                    

   COPD                                30 (52)             19 (45)             11 (69)             0.146

   Interstitial lung disease           10 (17)             6 (14)              4 (25)              0.439

   Hypertension                        24 (41)             16 (38)             8 (50)              0.552

   Diabetes mellitus                   18 (31)             15 (36)             3 (19)              0.342

   Other malignancies                  10 (17)             7 (17)              3 (19)              1.0

  Pulmonary function test                                                                          

   FEV~1~ % predicted postoperative    63 (54--75)         65 (55--75)         60 (51--75)         0.596

   DL~CO~ % predicted postoperative    51 (44--61)         53 (46--63)         48 (38--51)         0.070

  Clinical stage                                                                                   0.465

   I                                   22 (38)             18 (43)             4 (25)              

   II                                  21 (36)             14 (33)             7 (44)              

   III                                 15 (26)             10 (24)             5 (31)              

  Neoadjuvant treatment                11 (19)             5 (12)              6 (38)              0.055

  Side of operation                                                                                0.877

   Right                               36 (62)             25 (60)             11 (69)             

   Left                                20 (35)             15 (36)             5 (31)              

  Approach type                                                                                    0.217

   Open thoracotomy                    39 (67)             26 (62)             13 (81)             

   Minimal invasive surgery            19 (33)             16 (38)             3 (19)              

  Type of operation                                                                                0.767

   Partial resection                   4 (7)               3 (7)               1 (6)               

   Lobectomy                           43 (74)             32 (76)             11 (69)             

   Bilobectomy                         4 (7)               2 (5)               2 (13)              

   Pneumonectomy                       7 (12)              5 (12)              2 (13)              

  Total operation time, min            254 (180--318)      236 (178--337)      265 (221--300)      0.626

  One lung ventilation time, min       134 (100--199)      133 (100--199)      150 (113--229)      0.565

   Peak airway pressure, cmH~2~O       21 (18--23)         21 (18--23)         21 (17--25)         0.643

   Tidal volume, ml                    398 (364--424)      400 (378--427)      368 (344--421)      0.095

  Intraoperative volume infusion, ml   1750 (1238--2108)   1725 (1250--2025)   1750 (965--2200)    0.931

  Transfusion                          6 (10)              4 (10)              2 (13)              0.664

  Bleeding, ml                         300 (200--400)      300 (200--400)      300 (163--400)      0.854
  ------------------------------------------------------------------------------------------------------------

Data are presented as number (percentage) or as median (interquartile range).

ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DL~CO~, diffusing capacity for carbon monoxide; FEV~1~, forced expiratory volume in 1 second.

Clinical characteristics at the time of ALI diagnosis are presented in [Table 2](#table2-1753466619840256){ref-type="table"}. The median LIS and PF ratio of all patients were 2.0 (1.5--2.5) and 161 (142--207), respectively. A total of 43 (74%) patients required MV support, and 38 (66%) and 2 (3%) were classified as moderate and severe ARDS by the Berlin definition, respectively. There was no significant difference in the severity of ALI, laboratory findings except for CRP level, and treatments between the two groups ([Table 2](#table2-1753466619840256){ref-type="table"}).

###### 

Severity of acute lung injury and treatment modalities in the intensive care unit.

![](10.1177_1753466619840256-table2)

  ------------------------------------------------------------------------------------------------
                           Total\              Early treatment\    Late treatment\     *p* value
                           (*n* = 58)          (*n* = 42)          (*n* = 16)          
  ------------------------ ------------------- ------------------- ------------------- -----------
  SOFA score               4 (2--6)            4 (2--6)            5 (2--6)            0.464

  Severity of ALI                                                                      

   LIS                     2.0 (1.5--2.5)      2.0 (1.5--2.5)      2.0 (1.6--2.3)      0.833

   OI                      10.2 (6.9--14.2)    10.9 (6.9--13.9)    9.0 (6.3--15.9)     0.768

   PaO~2~/FiO~2~ ratio     161 (142--207)      160 (136--215)      167 (145--201)      0.770

  Laboratory data                                                                      

   pH                      7.42 (7.38--7.45)   7.41 (7.37--7.45)   7.42 (7.38--7.44)   0.520

   PaO~2~, mmHg            77 (66--88)         76 (65--88)         79 (68--89)         0.558

   PaCO~2~, mmHg           38 (33--42)         37 (33--42)         38 (32--45)         0.902

   HCO~3~, mmol/L          25 (22--26)         25 (22--26)         26 (24--27)         0.167

   CRP, mg/dL              19.9 (13.7--24.8)   21.4 (14.4--26.1)   17.5 (7.9--21.2)    0.013

  Mechanical ventilation   43 (74)             30 (71)             13 (81)             0.522

   FiO~2~                  0.5 (0.4--0.6)      0.5 (0.4--0.6)      0.5 (0.4--0.6)      0.571

   PEEP, cmH~2~O           6 (5--8)            6 (5--8)            5 (5--9)            0.858

   Above-PEEP, cmH~2~O     14 (12---15)        14 (12--15)         12 (12--16)         0.337

   Tidal volume, ml        370 (330--490)      350 (295--460)      440 (353--570)      0.112

  Corticosteroid                                                                       0.375

   Low dose                33 (57)             22 (52)             11 (69)             

   High dose               25 (43)             20 (48)             5 (31)              

  Tracheostomy             19 (33)             12 (29)             7 (44)              0.351

  CRRT                     8 (14)              5 (12)              3 (19)              0.672

  ECMO                     10 (17)             7 (17)              3 (19)              1.0

  Vasopressor              28 (48)             18 (43)             10 (63)             0.243

  Antibiotics              57 (98)             42 (100)            15 (94)             0.276
  ------------------------------------------------------------------------------------------------

Data are presented as number (percentage) or as median (interquartile range).

ALI, acute lung injury; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; FiO~2~, fraction of inspired oxygen; LIS, lung injury score; OI, oxygenation index; PaO~2~, partial pressure of oxygen in the arterial blood; PEEP, positive end-expiratory pressure; SOFA, sequential organ failure assessment.

Treatment outcomes of patients are summarized in [Table 3](#table3-1753466619840256){ref-type="table"}. Over the study period, 43 (74%) patients received MV support and 28 patients were weaned from MV. Of the 15 patients who failed to wean from MV, 13 (22%) died and 2 (4%) were transferred to other hospitals. Overall in-hospital mortality was 41%. In comparisons of outcomes between the two groups, the overall treatment response to corticosteroid was higher in the early treatment group compared with the late treatment group (95% *versus* 69%, *p* = 0.014). In detail, the early treatment group showed an improved LIS (86% *versus* 63%, *p* = 0.072) and were more likely to be successfully weaned from MV within 7 days (57% *versus* 39%, *p* = 0.332) compared with the late treatment group. Although successful weaning from MV in patients receiving MV support was not significantly different between the two groups, there was a trend toward less time to weaning from MV in the early treatment group compared with the late treatment group (*p* = 0.098 by the log-rank test; [Figure 1](#fig1-1753466619840256){ref-type="fig"}). Nonetheless, mortalities in the ICU and hospital were not different.

###### 

Treatment outcomes of patients with acute lung injury after pulmonary resection.

![](10.1177_1753466619840256-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                Total\        Early treatment\   Late treatment\   *p* value
                                                                                                (*n* = 58)    (*n* = 42)         (*n* = 16)        
  --------------------------------------------------------------------------------------------- ------------- ------------------ ----------------- -----------
  Response to corticosteroid treatment^[a](#table-fn7-1753466619840256){ref-type="table-fn"}^   51 (88)       40 (95)            11 (69)           0.014

   Weaning from MV within 7 days                                                                22 (51)       17 (57)            5 (39)            0.332

   Improvement in LIS                                                                           46 (79)       36 (86)            10 (63)           0.072

  Weaning from MV                                                                               28 (65)       21 (70)            7 (54)            0.305

  Complications during corticosteroid treatment                                                                                                    

   Arrhythmia                                                                                   17 (29)       11 (26)            6 (38)            0.520

   Delirium                                                                                     20 (35)       10 (24)            10 (63)           0.012

   Superimposed infection                                                                       25 (43)       18 (43)            7 (44)            1.0

  Surgical site complications                                                                                                                      0.356

   Persistent air leakage                                                                       18 (31)       13 (31)            5 (31)            

   Bleeding                                                                                     1 (2)         0                  1 (6)             

  ICU mortality                                                                                 21 (36)       15 (36)            6 (38)            1.0

  Length of ICU stay, days                                                                      9 (4--28)     8 (4--29)          17 (8--27)        0.247

  28-day mortality                                                                              7 (12)        6 (14)             1 (6)             0.660

  In-hospital mortality                                                                         24 (41)       18 (43)            6 (38)            0.773

  Length of hospital stay, days                                                                 33 (21--46)   30 (21--44)        37 (21--54)       0.254
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as number (percentage) or as median (interquartile range).

ICU, intensive care unit; LIS, lung injury score; MV, mechanical ventilation.

Defined as weaning from MV within 7 days or improvement in LIS, which was defined as follows: (1) a reduction in LIS of 1 point or more by study day 7 and (2) a day 7 LIS ⩽2.0 (for study entry LIS ⩽2.9) or ⩽2.5 (for study entry LIS ⩾3.0).

![Kaplan--Meier curves of the probability of weaning from mechanical ventilation in patients who received low-dose corticosteroid treatment within 72 h after development of acute lung injury following lung resection (early treatment group; dotted line) and those who received corticosteroids more than 72 h after development of acute lung injury (late treatment group; solid line).](10.1177_1753466619840256-fig1){#fig1-1753466619840256}

Regarding complications during corticosteroid treatment, delirium was significantly less common in the early treatment group compared with the late treatment group (24% *versus* 63%, *p* = 0.012). However, there was no difference in the development of infection and surgical site complications including persistent air leakage and bleeding between the two groups ([Table 3](#table3-1753466619840256){ref-type="table"}).

Discussion {#section13-1753466619840256}
==========

In this observational study, we demonstrated the beneficial effect of early administration of corticosteroid in patients with ALI after lung resection surgery for lung cancer. Corticosteroid treatment within 72 h after development of postoperative ALI was associated with a greater improvement of LIS than treatment after 72 h. In addition, there was a trend toward less time to weaning from MV in the early treatment group than in the late treatment group. Finally, there was no significant difference in the incidence of surgical site infection between the two groups.

During the study period, the overall prevalence rate of ALI was 0.8%, which is relatively low compared with previous studies reporting rates of 2.6--7% in pneumonectomy and 1--3% in lobectomy.^[@bibr2-1753466619840256][@bibr3-1753466619840256][@bibr4-1753466619840256][@bibr5-1753466619840256]--[@bibr6-1753466619840256]^ We ascribe our lower prevalence rate in part to our lung protective ventilation strategy during surgery.^[@bibr23-1753466619840256]^ A large tidal volume and high airway pressure during OLV is associated with an increased risk of postoperative ALI.^[@bibr24-1753466619840256],[@bibr25-1753466619840256]^ This is supported by a recent meta-analysis showing that the use of low tidal volume resulted in a lower incidence of ARDS in patients undergoing OLV.^[@bibr26-1753466619840256]^

The role of corticosteroid treatment in the management of ARDS has been systematically studied.^[@bibr11-1753466619840256][@bibr12-1753466619840256][@bibr13-1753466619840256][@bibr14-1753466619840256]--[@bibr15-1753466619840256]^ In a small randomized controlled trial,^[@bibr14-1753466619840256]^ early infusion (⩽72 h after onset of ARDS) of low-dose methylprednisolone was associated with significant improvement in pulmonary and extrapulmonary organ dysfunction. A recent analysis of individual patient data from four randomized trials combined with a trial-level meta-analysis of the updated literature demonstrated that early and prolonged corticosteroid treatment accelerated resolution of ARDS and decreased hospital mortality and healthcare utilization without increasing the risk of infection.^[@bibr27-1753466619840256]^ The beneficial effects of corticosteroids in ARDS are consistent with the hypothesis that fibroproliferation is an early response to lung injury that is inhibited by early low-dose corticosteroid treatment.^[@bibr28-1753466619840256]^ Despite many studies investigating corticosteroid therapy in ARDS, there is limited information on the therapy in ALI after lung resection, although Lee and colleagues^[@bibr18-1753466619840256]^ demonstrated a possible benefit of using low-dose corticosteroids in patients with ARDS after thoracotomy in a small observational study. In the present study, early initiation of corticosteroid demonstrated a higher ratio of improvement in LIS and a trend toward more successful weaning from MV, although the early treatment group showed a significantly higher level of CRP than the late treatment group, indicating more severe inflammation. More severe inflammatory markers might have led clinicians to initiate corticosteroid treatment in the early treatment group of this study. Despite more severe inflammation, patients of the early treatment group demonstrated a higher response to corticosteroid treatment and more successful weaning from MV compared with patients of the late treatment group. However, there was no significant difference in mortality between the early and late treatment group in this study. Our results, combined with the findings of other recent study not showing any beneficial effects of corticosteroid on mortality in patients with ARDS,^[@bibr29-1753466619840256]^ suggest that more studies are needed to prove its mortality benefit in ARDS.

Despite the beneficial effects of early low-dose corticosteroid treatment in ARDS, the suppressant effect of corticosteroids on wound healing and the immune response raises concern in patients undergoing lung resection. However, recent trials investigating low-dose corticosteroids in ARDS have not reported an increased rate of nosocomial infections.^[@bibr27-1753466619840256],[@bibr30-1753466619840256]^ In addition, neither wound infection nor anastomosis dehiscence was reported in an observational study of patients with postoperative ALI.^[@bibr18-1753466619840256]^ In the present study, prolonged air leakage was the main surgical site complication in patients receiving corticosteroid treatment, which is similar to the previous report by Lee and colleagues.^[@bibr18-1753466619840256]^

There are several limitations to our study that should be acknowledged. The limitations of this study are attributed primarily to univariate analysis with a relatively small sample size of the two groups, which were unable to perform additional statistical analyses including propensity matching or severity stratification of ALI. Another major limitation is the fact that we did not systematically screen patients with acute hypoxemic respiratory failure within 7 days after lung resection surgery. More severely ill patients might not have undergone chest CT scanning even if they were strongly suspected to have ALI. Data regarding how many patients with suspicion of ALI refused further evaluation could not be extracted from the medical records during the study period. In addition, given the retrospective nature of our study, there is the inherent possibility that selection bias may have influenced the significance of our findings. Furthermore, since our study did not compare patients receiving corticosteroids with those not receiving corticosteroids directly, we could not make a conclusion confirming its efficacy in postoperative ALI. Additional studies that are performed in larger, well-defined prospective cohorts are warranted to address the issue. Finally, our study was from a single institution with the largest number of lung cancer surgeries performed in Korea for the last 10 years, which limits the generalization of our findings to other institutions.

In summary, early administration of corticosteroid in patients with ALI after lung resection surgery for lung cancer was associated with greater improvement of lung injury and reduced time to weaning from MV, without affecting operative wound healing. However, further evaluation with a prospective, randomized, controlled study is needed to confirm these observations.
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